
Opinion|Videos|August 7, 2024
EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer
Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5















